StockData
Takeda Pharmaceutical Co Ltd logo

Takeda Pharmaceutical Co Ltd

TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$21.77+0.36 (+1.68%)

Close on Nov 20, 2026Market cap $75.03BP/E –Yield –

Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow by Quarter

Net Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1)

Periods

Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow: 304.30 JPY billion in Q2 FY27, down 19.6% from a year earlier.

Latest, Q2 FY27
304.30
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
-19.6%
378.30 in Q2 FY26
History
18 quarters
Since Q1 FY23
Sources
14
Documents cited below

Where the Q2 FY27 figure comes from

Calculated from reported figures: Q2 = 6M year-to-date − Q1 (YTD − prior YTD)

Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗

Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Cash from Operating Activities (Operating Cash Flow — Exhibit 99.1)Year on yearSource
Q2 FY27CQ3 2026Sep 30, 2026304.30-19.6%SEC EDGAR Filing (exhibit991_102926.htm) ↗
Q1 FY27CQ2 2026Jun 30, 2026127.60-40.8%SEC EDGAR Filing (exhibit991_073026.htm) ↗
Q4 FY26CQ1 2026Mar 31, 202674.50-66.5%SEC EDGAR Filing (exhibit991.htm) ↗
Q3 FY26CQ4 2025Dec 31, 2025373.20-2.7%SEC EDGAR Filing (exhibit991_012926.htm) ↗
Q2 FY26CQ3 2025Sep 30, 2025378.30+34.6%SEC EDGAR Filing (exhibit991_102926.htm) ↗
Q1 FY26CQ2 2025Jun 30, 2025215.40+26.5%SEC EDGAR Filing (exhibit991_073025.htm) ↗
Q4 FY25CQ1 2025Mar 31, 2025222.20-20.2%SEC EDGAR Filing (exhibit991.htm) ↗
Q3 FY25CQ4 2024Dec 31, 2024383.70+161.9%SEC EDGAR Filing (exhibit991_012926.htm) ↗
Q2 FY25CQ3 2024Sep 30, 2024281.00+41.3%SEC EDGAR Filing (exhibit991_103025.htm) ↗
Q1 FY25CQ2 2024Jun 30, 2024170.30+84.3%SEC EDGAR Filing (exhibit991_073124.htm) ↗
Q4 FY24CQ1 2024Mar 31, 2024278.50-5.2%SEC EDGAR Filing (exhibit991_050825.htm) ↗
Q3 FY24CQ4 2023Dec 31, 2023146.50-61.3%SEC EDGAR Filing (exhibit991_013025.htm) ↗
Q2 FY24CQ3 2023Sep 30, 2023198.90-10.0%SEC EDGAR Filing (exhibit991_103124.htm) ↗
Q1 FY24CQ2 2023Jun 30, 202392.40+9.7%SEC EDGAR Filing (exhibit991_072723.htm) ↗
Q4 FY23CQ1 2023Mar 31, 2023293.70–SEC EDGAR Filing (exhibit991_050924.htm) ↗
Q3 FY23CQ4 2022Dec 31, 2022378.30–SEC EDGAR Filing (exhibit991_020124.htm) ↗

Cite this data

StockData. (2026). Takeda Pharmaceutical Net Cash from Operating Activities (Operating Cash Flow, quarterly Q1 FY23–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-ocf

See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?